HK1198386A1 - Pyridinone and pyrimidinone derivatives as factor xia inhibitors xia - Google Patents

Pyridinone and pyrimidinone derivatives as factor xia inhibitors xia

Info

Publication number
HK1198386A1
HK1198386A1 HK14111900.0A HK14111900A HK1198386A1 HK 1198386 A1 HK1198386 A1 HK 1198386A1 HK 14111900 A HK14111900 A HK 14111900A HK 1198386 A1 HK1198386 A1 HK 1198386A1
Authority
HK
Hong Kong
Prior art keywords
xia
pyridinone
inhibitors
pyrimidinone derivatives
factor
Prior art date
Application number
HK14111900.0A
Other languages
English (en)
Chinese (zh)
Inventor
Steve Courtney
Chris Yarnold
Stuart Flanagan
Gareth Brace
John Barker
Osamu Ichihara
Elise Gadouleau
Anthony Richardson
Takashi Kondo
Akira Imagawa
Shingo Nakatani
Ryo Suzuki
Sho Kouyama
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB1122139.7A external-priority patent/GB2497806A/en
Priority claimed from GB201217290A external-priority patent/GB201217290D0/en
Application filed filed Critical
Publication of HK1198386A1 publication Critical patent/HK1198386A1/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/06Antiarrhythmics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
HK14111900.0A 2011-12-21 2014-11-25 Pyridinone and pyrimidinone derivatives as factor xia inhibitors xia HK1198386A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1122139.7A GB2497806A (en) 2011-12-21 2011-12-21 Pyridinone and pyrimidinone derivatives as factor XIa inhibitors
GB201217290A GB201217290D0 (en) 2012-09-27 2012-09-27 Compounds
PCT/GB2012/053217 WO2013093484A1 (en) 2011-12-21 2012-12-20 Pyridinone and pyrimidinone derivatives as factor xia inhibitors

Publications (1)

Publication Number Publication Date
HK1198386A1 true HK1198386A1 (en) 2015-04-17

Family

ID=47553259

Family Applications (1)

Application Number Title Priority Date Filing Date
HK14111900.0A HK1198386A1 (en) 2011-12-21 2014-11-25 Pyridinone and pyrimidinone derivatives as factor xia inhibitors xia

Country Status (23)

Country Link
US (2) US9732085B2 (de)
EP (2) EP2794597B1 (de)
JP (2) JP6137193B2 (de)
KR (1) KR102011534B1 (de)
CN (1) CN104136431B (de)
AU (1) AU2012356374B2 (de)
BR (1) BR112014015669B1 (de)
CA (1) CA2859604C (de)
DK (1) DK2794597T3 (de)
ES (2) ES2655669T3 (de)
HK (1) HK1198386A1 (de)
HU (1) HUE036010T2 (de)
IL (1) IL233154A (de)
IN (1) IN2014CN04676A (de)
MX (1) MX351471B (de)
NO (1) NO2794597T3 (de)
PH (1) PH12014501365B1 (de)
PL (1) PL2794597T3 (de)
PT (1) PT2794597T (de)
RU (1) RU2630677C2 (de)
SG (1) SG11201403402VA (de)
TW (1) TWI613199B (de)
WO (1) WO2013093484A1 (de)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2789622C (en) 2010-02-11 2018-04-03 Bristol-Myers Squibb Company Macrocycles as factor xia inhibitors
RU2606635C2 (ru) * 2011-07-13 2017-01-10 Сантен Фармасьютикал Ко., Лтд. Новое соединение, проявляющее ингибиторную активность в отношении parp
EP2766345B1 (de) 2011-10-14 2016-03-16 Bristol-Myers Squibb Company Substituierte tetrahydroisochinolinverbindungen als faktor-xia-hemmer
JP6033318B2 (ja) 2011-10-14 2016-11-30 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company 第XIa因子阻害剤としての置換テトラヒドロイソキノリン化合物
AU2012322085B2 (en) 2011-10-14 2017-05-04 Bristol-Myers Squibb Company Substituted tetrahydroisoquinoline compounds as factor Xia inhibitors
NO2794597T3 (de) * 2011-12-21 2018-04-14
JP2015503504A (ja) * 2011-12-23 2015-02-02 ミレニアム ファーマシューティカルズ, インコーポレイテッドMillennium Pharmaceuticals, Inc. ヘテロアリールおよびその使用
TW201416362A (zh) 2012-07-19 2014-05-01 Dainippon Sumitomo Pharma Co 1-(環烷基羰基)脯胺酸衍生物
WO2014022766A1 (en) 2012-08-03 2014-02-06 Bristol-Myers Squibb Company Dihydropyridone p1 as factor xia inhibitors
JP6082463B2 (ja) 2012-08-03 2017-02-15 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company 第xia因子阻害剤としてのジヒドロピリドンp1
ES2668318T3 (es) 2012-10-12 2018-05-17 Bristol-Myers Squibb Company Formas cristalinas de inhibidor del factor XIa
US9403774B2 (en) 2012-10-12 2016-08-02 Bristol-Myers Squibb Company Guanidine and amine substituted tetrahydroisoquinoline compounds as factor xia inhibitors
US9315519B2 (en) 2012-10-12 2016-04-19 Bristol-Myers Squibb Company Guanidine substituted tetrahydroisoquinoline compounds as factor XIa inhibitors
EP2978751B1 (de) 2013-03-25 2018-12-05 Bristol-Myers Squibb Company Tetrahydroisochinoline mit substituierten azolen als faktor-xia-hemmern
WO2014160592A2 (en) * 2013-03-27 2014-10-02 Merck Sharp & Dohme Corp. FACTOR XIa INHIBITORS
TWI633089B (zh) * 2013-03-28 2018-08-21 拜耳製藥股份有限公司 經取代的酮基吡啶衍生物
WO2015011087A1 (de) * 2013-07-23 2015-01-29 Bayer Pharma Aktiengesellschaft Substituierte oxopyridin-derivate und ihre verwendung als faktor xia / plasma
CN105849109B (zh) * 2013-10-30 2018-01-23 拜耳制药股份公司 取代的氧代吡啶衍生物
JP6464176B2 (ja) * 2014-01-31 2019-02-06 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company 芳香族p2’基を有する第xia因子阻害剤としてのマクロ環
NO2760821T3 (de) 2014-01-31 2018-03-10
EP3104703B1 (de) 2014-02-11 2020-11-18 Merck Sharp & Dohme Corp. Faktor-xia-hemmer
US9676723B2 (en) 2014-02-11 2017-06-13 Merck Sharp & Dohme Corp Factor XIa inhibitors
CN105829298B (zh) * 2014-02-14 2019-02-01 四川海思科制药有限公司 一种吡啶酮或嘧啶酮衍生物、及其制备方法和应用
WO2015164308A1 (en) 2014-04-22 2015-10-29 Merck Sharp & Dohme Corp. FACTOR XIa INHIBITORS
CN105658641B (zh) * 2014-07-25 2018-04-17 江苏恒瑞医药股份有限公司 氮茚‑酰胺类衍生物、其制备方法及其在医药上的应用
US9868727B2 (en) 2014-07-28 2018-01-16 Merck Sharp & Dohme Corp. Factor XIa inhibitors
ES2714283T3 (es) 2014-09-04 2019-05-28 Bristol Myers Squibb Co Macrociclos de diamida que son inhibidores de FXIa
CN104311537B (zh) * 2014-09-19 2016-08-24 广东东阳光药业有限公司 含有嘧啶酮乙酰基取代基吡唑类化合物及其组合物及用途
CN106687458B (zh) * 2014-09-24 2020-10-27 拜耳制药股份公司 取代的氧代吡啶衍生物
ES2722423T3 (es) 2014-09-24 2019-08-12 Bayer Pharma AG Derivados de oxopiridina sustituidos
NO2721243T3 (de) * 2014-10-01 2018-10-20
US9453018B2 (en) 2014-10-01 2016-09-27 Bristol-Myers Squibb Company Pyrimidinones as factor XIa inhibitors
KR102525392B1 (ko) * 2014-12-10 2023-04-24 오노 야꾸힝 고교 가부시키가이샤 디히드로인돌리지논 유도체
GB201506658D0 (en) 2015-04-20 2015-06-03 Cellcentric Ltd Pharmaceutical compounds
RU2649141C2 (ru) * 2015-04-20 2018-03-30 государственное бюджетное образовательное учреждение высшего профессионального образования "Пермская государственная фармацевтическая академия" Министерства здравоохранения Российской Федерации (ГБОУ ВПО ПГФА Минздрава России) 3,4-диметил-6-(3-пиридил)-N-фенил-2-оксо-1,2,3,6-тетрагидропиримидин-5-карбоксамид, проявляющий противогрибковое действие в отношении штамма Candida albicans
GB201506660D0 (en) 2015-04-20 2015-06-03 Cellcentric Ltd Pharmaceutical compounds
JO3703B1 (ar) * 2015-07-09 2021-01-31 Bayer Pharma AG مشتقات أوكسوبيريدين مستبدلة
RU2653511C2 (ru) * 2015-07-29 2018-05-10 государственное бюджетное образовательное учреждение высшего профессионального образования "Пермская государственная фармацевтическая академия" Министерства здравоохранения Российской Федерации (ГБОУ ВПО ПГФА Минздрава России) 4-метил-n-2,4-диметилфенил-6-(3-фторфенил)-2-тиоксо-1,2,3,6-тетрагидропиримидин-5-карбоксамид, проявляющий анальгетическое действие
US10336730B2 (en) 2015-08-05 2019-07-02 Bristol-Myers Squibb Company Substituted glycine derived FXIA inhibitors
CN106496249B (zh) * 2015-09-07 2019-12-13 江苏恒瑞医药股份有限公司 噁唑并吲哚类衍生物、其制备方法及其在医药上的应用
EP3371162B1 (de) 2015-10-29 2022-01-26 Merck Sharp & Dohme Corp. Makrocyclische spirocarbamat-derivate als faktor-xia-inhibitoren, pharmazeutisch verträgliche zusammensetzungen und deren verwendung
CA2998902C (en) 2015-10-29 2024-03-26 Merck Sharp & Dohme Corp. Macrocyclic compounds as factor xia inhibitors
JP6992284B2 (ja) * 2016-06-06 2022-01-13 小野薬品工業株式会社 ジヒドロインドリジノン誘導体を含有する医薬組成物
US10143681B2 (en) 2016-08-22 2018-12-04 Merck Sharp & Dohme Corp. Factor XIa inhibitors
EP3486242B1 (de) * 2016-08-31 2021-12-08 Jiangsu Hengrui Medicine Co., Ltd. Oxopicolinamid-derivat, herstellungsverfahren dafür und pharmazeutische verwendung davon
EP3305538A1 (de) 2016-10-07 2018-04-11 Mitsubishi HiTec Paper Europe GmbH Wärmeempfindliches aufzeichnungsmaterial
DE202017006776U1 (de) 2016-10-07 2018-05-16 Mitsubishi Hitec Paper Europe Gmbh Wärmeempfindliches Aufzeichnungsmaterial
CN106950319B (zh) * 2017-04-20 2019-08-30 西安科技大学 一种检测特鲁曲班光学异构体含量的方法
CN109507345B (zh) * 2017-09-15 2022-08-05 万特制药(海南)有限公司 重酒石酸卡巴拉汀中间体及其杂质的分离测定方法
CA3091528A1 (en) * 2018-02-27 2019-09-06 Jiangsu Hengrui Medicine Co., Ltd. Crystal form of oxopicolinamide derivative and preparation method therefor
US11225462B2 (en) 2018-07-02 2022-01-18 Jiangsu Hengrui Medicine Co., Ltd. Crystal forms of oxypyridine amide derivative and preparation method therefor
TWI825144B (zh) * 2018-08-10 2023-12-11 美商思達利醫藥公司 第二型轉麩醯胺酸酶(tg2)抑制劑
WO2020094156A1 (zh) * 2018-11-11 2020-05-14 上海海雁医药科技有限公司 双杂环取代的吡啶-2(1h)-酮衍生物、其制法与医药上的用途
JP7196931B2 (ja) * 2018-11-30 2022-12-27 小野薬品工業株式会社 (3s)-3-[2-(6-アミノ-2-フルオロピリジン-3-イル)-4-フルオロ-1h-イミダゾール-5-イル]-7-[5-クロロ-2-(1h-テトラゾール-1-イル)フェニル]-2,3-ジヒドロインドリジン-5(1h)-オンの新規結晶
CN109836360B (zh) * 2019-03-19 2021-08-13 南京恩泰医药科技有限公司 一种甲苯磺酸依度沙班中间体的制备方法及中间体化合物
CN112028877B (zh) * 2019-06-04 2021-11-26 江西济民可信集团有限公司 烷氧吡啶酮化合物及其制备方法和用途
CA3145111C (en) * 2019-06-28 2023-01-24 Shanghai Jemincare Pharmaceuticals Co., Ltd Tricyclic compound, preparation method therefor and use thereof
JP7450024B2 (ja) * 2019-09-27 2024-03-14 シェンヅェン サルブリス ファーマシューティカルズ カンパニー リミテッド FXIa阻害剤及びその調製方法と医薬用途
CN112778277B (zh) * 2019-11-11 2024-04-02 江西济民可信集团有限公司 环酮并吡啶酮联杂芳环化合物及其制备方法和用途
EP4185587A1 (de) * 2020-07-22 2023-05-31 JANSSEN Pharmaceutica NV Verbindungen als faktor-xia-hemmer
WO2023002984A1 (ja) * 2021-07-20 2023-01-26 小野薬品工業株式会社 イミダゾール化合物の製造方法
US11958856B2 (en) 2021-07-22 2024-04-16 Janssen Pharmaceutica Nv Substituted 1,2,3,8,9,9a-hexahydro-5H-pyrrolo[1,2-a]azepin-5-ones as factor XIa inhibitors
US20230097157A1 (en) * 2021-07-22 2023-03-30 Janssen Pharmaceutica Nv Bicyclic Pyridin-2-one and pyrimidin-4-one Derivatives Useful As a Factor XIa Inhibitors
CN113735770B (zh) * 2021-09-30 2023-06-06 四川大学 一种铑催化的4-苯基噁二唑酮与碳酸亚乙烯酯合成1-氨基异喹啉骨架的方法
TWI833610B (zh) * 2022-03-21 2024-02-21 大陸商上海濟煜醫藥科技有限公司 三并環類化合物製備方法及其中間體
CN118406037A (zh) * 2024-06-25 2024-07-30 四川师范大学 一种三氮唑类衍生物及其制备方法和用途

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0042675A1 (de) 1980-06-20 1981-12-30 Norton Company Verfahren zum Befestigen einer Schleifscheibe auf einer Spindel
EP0224283A3 (de) 1982-05-18 1988-09-21 University Of Florida Gehirnspezifische Arzneimittelabgabe
CA1241120A (en) 1985-10-01 1988-08-23 Sami A. Aly Alternate mark inversion (ami) receiver
CA1334092C (en) * 1986-07-11 1995-01-24 David John Carini Angiotensin ii receptor blocking imidazoles
EP0407342A3 (en) * 1989-07-06 1991-07-10 Ciba-Geigy Ag Pyrimidine derivatives
DE4221583A1 (de) * 1991-11-12 1993-05-13 Bayer Ag Substituierte biphenylpyridone
DE4407488A1 (de) 1994-03-07 1995-09-14 Bayer Ag Verwendung von Biphenyl- und Pyridylmethylpyridonen
JP4164031B2 (ja) 2002-02-14 2008-10-08 ファルマシア コーポレーション P38mapキナーゼのモジュレータとしての置換されたピリジノン
EP1506967B1 (de) 2003-08-13 2007-11-21 Takeda Pharmaceutical Company Limited Dipeptidyl Peptidase Inhibitoren.
GB0420722D0 (en) * 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
US20080207616A1 (en) 2004-10-15 2008-08-28 Astrazeneca Ab Quinoxalines as B Baf Inhhibitors
EP1833794B1 (de) 2004-11-24 2012-02-01 Vertex Pharmceuticals Incorporated 3-[2-(3-azylamino-2-oxo-2h-pyridin-1-yl)acetylamino]-4-oxopentansäurederivate und deren verwendung als caspase-inhibitoren
AR056682A1 (es) 2005-07-29 2007-10-17 Kalypsys Inc COMPUESTOS MULTICíCLICOS DERIVADOS DE LA SULFONAMIDA COMO INHIBIDORES DE LA HISTONA DESACETILASA Y COMPOSICIoN FARMACÉUTICA
ES2365815T3 (es) * 2005-12-14 2011-10-11 Bristol-Myers Squibb Company Análogos de arilpropionamida, arilacrilamida, arilpropinamida o arilmetilurea como inhibidores del factor xia.
ATE511502T1 (de) 2005-12-14 2011-06-15 Bristol Myers Squibb Co Arylpropionamid-, arylacrylamid-, arylpropinamid- oder arylmethylharnstoffanaloge als faktor-xia- inhibitoren
US20080207654A1 (en) * 2006-11-24 2008-08-28 Takeda Pharmaceutical Company Limited Heteromonocyclic compound and use thereof
WO2008076805A2 (en) 2006-12-15 2008-06-26 Bristol-Myers Squibb Company Arylpropionamide, arylacrylamide, arylpropynamide, or arylmethylurea analogs as factor xia inhibitors
MX2010006379A (es) 2007-12-11 2010-09-07 Schering Corp Moduladores de la secretasa gamma.
US8324199B2 (en) * 2008-03-13 2012-12-04 Bristol-Myers Squibb Company Pyridazine derivatives as factor xia inhibitors
US8946426B2 (en) 2009-02-06 2015-02-03 Janssen Pharmaceuticals, Inc. Substituted bicyclic heterocyclic compounds as gamma secretase modulators
CN103261176B (zh) 2010-10-07 2015-06-03 武田药品工业株式会社 1,4-氧杂氮杂环庚烷衍生物
NO2794597T3 (de) * 2011-12-21 2018-04-14

Also Published As

Publication number Publication date
PT2794597T (pt) 2018-01-16
IL233154A (en) 2016-12-29
EP3290413B1 (de) 2019-11-13
TWI613199B (zh) 2018-02-01
EP2794597A1 (de) 2014-10-29
NO2794597T3 (de) 2018-04-14
CN104136431B (zh) 2017-03-15
US9732085B2 (en) 2017-08-15
US20150152112A1 (en) 2015-06-04
NZ626176A (en) 2015-09-25
PH12014501365A1 (en) 2014-09-22
EP2794597B1 (de) 2017-11-15
JP6137193B2 (ja) 2017-05-31
DK2794597T3 (en) 2018-01-15
CN104136431A (zh) 2014-11-05
RU2630677C2 (ru) 2017-09-12
BR112014015669B1 (pt) 2021-10-13
MX2014007269A (es) 2014-07-22
KR102011534B1 (ko) 2019-08-16
EP3290413A1 (de) 2018-03-07
WO2013093484A1 (en) 2013-06-27
HUE036010T2 (hu) 2018-06-28
ES2765891T3 (es) 2020-06-11
KR20140103286A (ko) 2014-08-26
BR112014015669A2 (pt) 2017-06-13
PL2794597T3 (pl) 2018-03-30
JP6447660B2 (ja) 2019-01-09
BR112014015669A8 (pt) 2017-07-04
ES2655669T3 (es) 2018-02-21
JP2015500868A (ja) 2015-01-08
CA2859604C (en) 2019-12-17
IL233154A0 (en) 2014-08-03
IN2014CN04676A (de) 2015-09-18
TW201339157A (zh) 2013-10-01
MX351471B (es) 2017-10-17
EP3290413B9 (de) 2020-04-29
AU2012356374A8 (en) 2014-08-07
US10717738B2 (en) 2020-07-21
US20170305917A1 (en) 2017-10-26
CA2859604A1 (en) 2013-06-27
AU2012356374A1 (en) 2014-07-10
AU2012356374B2 (en) 2017-06-22
RU2014129797A (ru) 2016-02-10
SG11201403402VA (en) 2015-01-29
JP2017160239A (ja) 2017-09-14
PH12014501365B1 (en) 2014-09-22

Similar Documents

Publication Publication Date Title
HK1198386A1 (en) Pyridinone and pyrimidinone derivatives as factor xia inhibitors xia
HRP20181310T1 (hr) Novi heterociklički derivati i njihova uporaba
HK1209109A1 (en) Pyridinone and pyridazinone derivatives
HK1209739A1 (en) Pyridazine and pyridine derivatives as nampt inhibitors nampt
IL237011A0 (en) Dihydropyridone p1 as factor xia inhibitors
EP2703401A4 (de) Pyridinderivat und bace-1-hemmer damit
IL237012A0 (en) Dihydropyridone p1 as factor xia inhibitors
HK1198433A1 (en) N-acyldipeptide derivatives and their uses n-
ZA201405486B (en) Pyridone derivatives
AP4055A (en) Dihydro-benzo-oxazine and dihydro-pyrido-oxazine derivatives
EP2751084A4 (de) Yrimidincarboxamidderivate
EP2558094A4 (de) Pyridonderivate
EP2922543A4 (de) Substituierte pyridonderivate als pde10-hemmer

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20221216